LLY vs. NVO: Valuation Gaps Emerge in the GLP-1 Weight-Loss Market
Key Takeaways
-
Eli Lilly (LLY) has significantly outperformed, posting roughly 40% gains year to date, while Novo Nordisk (NVO) has fallen about 40% amid broader market and company-specific pressures.
-
Both companies dominate the GLP-1 market for diabetes and obesity, but LLY’s higher valuation reflects stronger momentum, broader pipeline diversification, and accelerating revenue growth.
-
NVO’s recent FDA approval of an oral version of its leading weight-loss therapy represents a potential inflection point and reinforces its appeal as a value opportunity.
-
Pricing pressure in competitive markets, including China, highlights shared risks from patent expirations and generic competition, though LLY continues to post superior profitability metrics.
-
Healthcare megatrends support long-term demand for both firms, but NVO’s lower P/E ratio suggests greater upside for valuation-focused investors as sentiment stabilizes.
-
Recent catalysts—manufacturing expansions at LLY and strategic adjustments at NVO—underscore resilience in a fast-growing yet volatile pharmaceutical landscape.
Introduction
Eli Lilly and Novo Nordisk are among the most influential pharmaceutical companies in the rapidly expanding GLP-1 receptor agonist market, which targets diabetes and obesity. As competition intensifies and regulatory and pricing dynamics evolve, the divergence in their stock performance has become increasingly pronounced. Growth-oriented investors may gravitate toward LLY’s momentum and pipeline breadth, while value-focused investors may view NVO’s recent pullback as an opportunity. This comparison examines performance trends, valuation differences, and strategic developments in a sector expected to surpass $100 billion in annual revenue by the end of the decade.
Eli Lilly: Overview and Recent Performance
Eli Lilly is a U.S.-based pharmaceutical leader with a diversified portfolio spanning oncology, neuroscience, and endocrinology. Its GLP-1 therapies, including Mounjaro and Zepbound, have driven exceptional growth, with recent quarters delivering revenue increases exceeding 50% year over year.
LLY shares have maintained strong upward momentum despite volatility across the broader healthcare sector. Investor confidence has been reinforced by sustained demand for weight-loss treatments, positive clinical data, and aggressive manufacturing expansion plans involving multi-billion-dollar investments to scale production capacity. Strategic pricing actions in competitive markets have further supported growth. These factors have contributed to elevated valuation levels, with the stock trading near a P/E ratio of 52, reflecting expectations for continued earnings expansion and pipeline execution.
Novo Nordisk: Overview and Recent Performance
Novo Nordisk, headquartered in Denmark, focuses primarily on metabolic and rare diseases, with its semaglutide-based products Ozempic and Wegovy anchoring its GLP-1 leadership. The company has long been recognized for innovation in diabetes and obesity care.
After a prolonged period of weakness, NVO shares have shown signs of stabilization following key regulatory developments. Most notably, FDA approval of an oral version of its weight-loss therapy has expanded patient access and strengthened its competitive position. The company has also adjusted pricing in key growth markets to defend share against emerging generics. Despite these positives, ongoing challenges—including supply limitations and currency headwinds—have weighed on performance, leaving NVO trading at a more modest P/E ratio near 14.
AI Trading Bot Perspective
Tickeron’s Trend Trader for Beginners: Strategy for Large Cap Stocks (60min, TA) is applicable to stocks like LLY and NVO. This trend-following system uses machine learning and technical analysis to identify aligned short-, medium-, and long-term trends, executing long-only trades with disciplined risk controls. The strategy limits exposure through trailing stops and a fixed take-profit level, aiming for steady gains in favorable market conditions. Backtested results indicate an annualized return of approximately 26% across large-cap equities.
Head-to-Head Comparison
While both companies are leaders in GLP-1 therapies, their strategic profiles differ. LLY benefits from a broader pipeline that extends beyond obesity into oncology and neuroscience, supporting diversified revenue streams. NVO remains more concentrated in semaglutide-based products, which increases exposure to competitive and pricing risks.
Momentum clearly favors LLY, supported by strong earnings growth and sustained investor confidence. NVO, however, offers a contrasting profile: weaker recent performance but a substantially lower valuation that could amplify gains if sentiment improves. Both face risks from patent expirations and generic competition, particularly in emerging markets, though LLY’s larger market capitalization provides greater insulation from volatility. Overall sentiment favors LLY for premium growth exposure, while NVO attracts investors seeking recovery potential.
Tickeron AI Verdict
From a valuation and catalyst perspective, Tickeron’s AI would likely tilt toward Novo Nordisk at current levels, citing its discounted valuation and upside potential tied to regulatory approvals such as the oral GLP-1 formulation. That said, Eli Lilly remains a compelling choice for growth-focused portfolios, supported by strong profitability, pipeline depth, and sustained demand. Investor outcomes will ultimately depend on competitive execution and the evolving dynamics of the global obesity treatment market.
Disclaimers and Limitations
LLY sees MACD Histogram just turned negative
LLY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 33 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 53 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
LLY moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for LLY entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LLY's RSI Indicator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 263 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement